Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E21.64 EPS (ttm)7.41 Insider Own0.10% Shs Outstand760.32M Perf Week-4.50%
Market Cap121.92B Forward P/E15.20 EPS next Y10.55 Insider Trans-7.46% Shs Float756.79M Perf Month2.08%
Income5.71B PEG1.88 EPS next Q2.40 Inst Own82.70% Short Float1.29% Perf Quarter5.88%
Sales20.58B P/S5.93 EPS this Y0.90% Inst Trans0.25% Short Ratio2.82 Perf Half Y1.85%
Book/sh34.83 P/B4.60 EPS next Y10.16% ROA8.20% Target Price182.26 Perf Year45.00%
Cash/sh35.67 P/C4.50 EPS next 5Y11.53% ROE22.40% 52W Range107.31 - 173.60 Perf YTD1.20%
Dividend3.16 P/FCF21.01 EPS past 5Y8.20% ROI10.20% 52W High-7.63% Beta0.49
Dividend %1.97% Quick Ratio5.10 Sales past 5Y6.50% Gross Margin80.70% 52W Low49.43% ATR4.07
Employees17900 Current Ratio5.50 Sales Q/Q11.30% Oper. Margin37.00% RSI (14)45.84 Volatility3.01% 2.24%
OptionableYes Debt/Eq1.14 EPS Q/Q50.70% Profit Margin27.70% Rel Volume0.94 Prev Close157.91
ShortableYes LT Debt/Eq1.13 EarningsApr 21 AMC Payout34.90% Avg Volume3.45M Price160.36
Recom2.40 SMA20-1.59% SMA50-0.45% SMA2006.95% Volume3,260,388 Change1.55%
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
Jan-24-13Reiterated UBS Buy $96 → $98
May-01-15 12:59PM  AMGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhi
12:04PM  The Compelling Case For Dividend Paying Stocks at Forbes
11:49AM  A Biotech Bottom? at Barrons.com
05:52AM  Boost for Oncolytic Viruses - Amgen''s T-Vec Approved by FDA Advisory Committee at noodls
Apr-30-15 01:04PM  AMGEN INC Financials
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Celladon, Kite Pharma, Pharmacyclics and Vertex Pharmaceuticals - Press Releases
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Celladon, Biogen, Celgene and Gilead - Press Releases
Apr-29-15 08:15PM  10-Q for Amgen, Inc. at Company Spotlight
06:14PM  Final Glance: Biotechnology companies
05:05PM  FDA panel recommends approval for Amgen's skin cancer immunotherapy Reuters
05:05PM  FDA Panel Gives Thumbs-Up To Amgen's Virus-Based Melanoma Drug at Forbes
04:15PM  35-year biotech industry veteran: The days of giant R&D investments are gone at bizjournals.com
03:44PM  Pfizer (PFE) Earnings Analysis: By the Numbers
02:53PM  Midday Glance: Biotechnology companies
02:37PM  Celldex 1Q Loss Narrower-Than-Expected, Pipeline in Focus - Analyst Blog
01:51PM  A Big Test for a big Biotech ETF
12:42PM  Amgen's Decline Could Be A Good Thing
12:08PM  [Podcast] Biogen is closing in on the holy grail for biotech stocks
11:08AM  3 Stable Large-Cap Biotech Stocks to Buy Now - Analyst Blog
10:45AM  Early Glance: Biotechnology companies
09:41AM  Amgen Announces FDA Advisory Committee Meeting To Review Repatha (Evolocumab) As A Treatment For High Cholesterol at noodls
09:30AM  The Zacks Analyst Blog Highlights: Celladon, Amgen, Biogen and Alnylam Pharmaceuticals - Press Releases
09:15AM  Amgen Announces FDA Advisory Committee Meeting To Review Repatha (Evolocumab) As A Treatment For High Cholesterol PR Newswire
08:41AM  Amgen To Discuss Details Of The Biologics License Application For Talimogene Laherparepvec For Patients With Metastatic Melanoma at noodls
08:04AM  Biotech Stock Roundup: Weakness in Biotech Sector on Amgen & Celladon News - Analyst Blog
08:00AM  Amgen To Discuss Details Of The Biologics License Application For Talimogene Laherparepvec For Patients With Metastatic Melanoma PR Newswire
Apr-28-15 05:08PM  Treasury market sells off ahead of Fed meeting at MarketWatch
05:07PM  Oracle leads US corporate bonds sale surge at Financial Times
03:41PM  Oracle, Amgen Latest to Issue Bonds to Fund Buybacks at Barrons.com
02:14PM  Oracle Joins Amgen in Planning $13.5 Billion of Bond Deals at Bloomberg
01:33PM  5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog
01:15PM  Apple sweetens S&P 500 buyback and dividend boom at Financial Times
11:30AM  Merck (MRK) Beats on Q1 Earnings & Revenues, Ups View - Analyst Blog
11:23AM  3 Biotech Stocks Still Attractive After Monday's Sell-Off - Analyst Blog
09:50AM  No Bounce for Biotech at Barrons.com
09:40AM  Pfizer Beats on Q1 Earnings, Cuts View on Currency Woes - Analyst Blog
Apr-27-15 05:27PM  Anticlimactic: Stocks Sink After Record Breaking Week at Barrons.com
05:11PM  More Preliminary Signs That The New Cholesterol Drugs May Improve Outcomes at Forbes
05:01PM  US STOCKS-Wall St ends down as biotechs drop 4 pct; Apple up late
04:38PM  US STOCKS-Wall St ends down as biotechs drop 4 pct
04:30PM  Biotechs stick it to stocks at CNBC
03:07PM  There Go the Biotechs at Barrons.com
03:02PM  ImmunoGen skids after disclosing drug development setbacks
02:50PM  US STOCKS-Wall St slips as biotechs drop; Apple shares up
01:16PM  Biotechs Weigh On Nasdaq, But Apple, Twitter Hold Firm at Investor's Business Daily
12:59PM  US STOCKS-Wall St reverses course to trade lower as health stocks drag
11:11AM  Amgen's cancer immunotherapy fails to impress FDA staff reviewers Reuters
08:38AM  FDA staff cite concerns over Amgen's cancer vaccine data Reuters
08:30AM  Short Sellers Become More Wary of Big Biotech at 24/7 Wall St.
06:19AM  AMGEN INC Files SEC form 10-Q, Quarterly Report
Apr-25-15 09:10AM  Massive Energy Trade Highlights High-Profile Insider Selling This Week at 24/7 Wall St.
Apr-24-15 04:31PM  Stock Market Video Analysis for Week Ending 4/24/15
03:16PM  Eli Lilly (LLY) Earnings Analysis: By the Numbers
09:58AM  Seattle Genetics' exec: Here's how to stay an independent biotech in Seattle at bizjournals.com
Apr-23-15 05:00PM  Kemper Freeman still unsure Expedia is moving to Seattle at bizjournals.com
02:14PM  AbbVie Profit Rises on Broad Sales Growth at The Wall Street Journal
10:48AM  AbbVie raises outlook as Humira again delivers earnings beat
10:30AM  3 Top Stocks to Buy That Delivered Great Earnings at 24/7 Wall St.
09:47AM  AbbVie raises guidance after 1Q sales beat
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Medicines, Athersys and Alnylam - Press Releases
08:50AM  Top Analyst Upgrades and Downgrades: Barrick, Facebook, Halcon, Qualcomm, Synchrony, Texas Instruments and More at 24/7 Wall St.
03:57AM  Novartis starts to reap rewards of revamp at Financial Times
Apr-22-15 01:21PM  Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
11:53AM  Stocks Mildly Higher; China Nods To Visa, MasterCard at Investor's Business Daily
11:43AM  Technological Innovation Increases Amgens Earnings and Stock Price
11:43AM  Amgen: But What About the Biosimilars? at Barrons.com
10:18AM  Amgen Earnings Reveals Ugly Truth About Drug Pricing and Sales 'Growth' at TheStreet
09:15AM  Amgen Beats on Q1 Earnings & Revenues, Ups Earnings View - Analyst Blog
08:29AM  Amgen (AMGN) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
07:58AM  Early movers: BA, KO, TMO, NLSN, AN & more at CNBC
06:30AM  Amgen tops estimates, grows profit 51% AAP
04:43AM  Roche boosted by US drugs sales at Financial Times
Apr-21-15 07:27PM  Amgen tops estimates with 51 percent spike in 1Q profit
06:28PM  Amgen earnings boosted by higher drug prices, lower R&D
06:00PM  Amgen, Illumina Earnings Hot, Intuitive Surgical Not at Investor's Business Daily
05:18PM  Amgen raises full-year guidance
05:13PM  After-hours buzz: Amgen, Yahoo, Chipotle & more at CNBC
05:04PM  Amgen tops Street 1Q forecasts
05:00PM  Amgen Profit Beats Estimates as Drugmaker Raises Forecast at Bloomberg
05:00PM  Amgen Inc Earnings Call scheduled for 5:00 pm ET today
04:52PM  Amgen earnings top analyst forecasts at Los Angeles Times
04:38PM  Amgen Jump in After Hours on Higher Earnings, Guidance at Barrons.com
04:37PM  Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 at noodls
04:29PM  Amgen Earnings Point to More Froth in the Biotech Sector at 24/7 Wall St.
04:28PM  Amgen (AMGN) Stock Gains in After-Hours Trading Today on Earnings Beat and Raised Guidance at TheStreet
04:24PM  Amgen 1st-quarter profit boosted by drug price rises, lower R&D
04:19PM  Earnings Parade: Chipotle & Yum
04:16PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:09PM  Amgen handily beats Street on strong drug sales at CNBC
04:05PM  Amgen beats on top & bottom line
04:01PM  Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48 PR Newswire
03:13PM  Strategist: Amgen To Move 3% On Q1 Earnings News
02:29PM  Adam Sarhan: Amgen Shares To Go Higher Following Q1 Results
02:04PM  What The Street...And The Crowd Are Watching At Amgen Before Earnings
11:35AM  Will Amgen Earnings Shape Biotech for the Rest of 2015? at 24/7 Wall St.
10:32AM  Stocks mixed amid earnings; Nasdaq leads gains at CNBC
08:08AM  Wall Street optimistic on bumper earnings day at CNBC
07:07AM  Q1 2015 Amgen Inc Earnings Release - After Market Close
Apr-20-15 03:20PM  Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog
03:08PM  TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM